Bayer Leaps to invests 1.3bn externally
German Bayer AG has announced it will channel at least 1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
Avantium closes financing for FDCA plant
/in News/by Thomas GabrielczykAvantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF.
Novo Holdings co-leads 40m Qure.ai financing
/in News/by Thomas GabrielczykDeep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad
XNK Therapeutics AB raises 12.75m
/in News/by Thomas GabrielczykXNK Therapeutics AB has secured a private placement of 12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.
Sanofi and IGM Biosciences Inc. in $6.15bn deal
/in News/by Thomas GabrielczykSanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.
CSL Behring files for MAA of haemophilia B gene therapy
/in News/by Thomas GabrielczykCSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Argenx SE to raise 637m
/in News/by Thomas GabrielczykDutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
Bayer invests into synthetic TCRs for cell therapy
/in News/by Thomas GabrielczykTCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Switzerland paves the way for genome editing
/in News/by Thomas GabrielczykSwitzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.
Gilde Healthcare Private Equity IV launches 517m
/in News/by Thomas GabrielczykGilde Healthcare Private Equity IV (GHPE IV) has closed at 517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.